Pfizer completes $17-billion Hospira acquisition

4 September 2015

US pharma giant Pfizer (NYSE: PFE) said it has completed the $17-billion acquisition of Hospira (NYSE: HSP), following which the shares of biosimilar injectables specialist ceased trading on the New York Stock Exchange.

Pfizer said the shareholders of Hospira are now entitled to receive $90 per share in cash for every share of Hospira common stock they owned as of September 3, 2015.

The drugmaker maintains the transaction will immediately add to its earnings by $0.10 - $0.12 per share in the first full year after the close, saying it sees incremental addition from the deal going forward. Additionally, Pfizer expects the transaction will deliver $800 million in annual cost synergies by 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK